Marc Beaudoin - Sunshine Biopharma Chief Officer
| SBFM Stock | USD 2.44 0.08 3.39% |
Executive
Marc Beaudoin is Chief Officer of Sunshine Biopharma
| Age | 57 |
| Address | 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301 |
| Phone | 954-515-0810 |
| Web | https://sunshinebiopharma.com |
Sunshine Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.21. At this time, Sunshine Biopharma's Debt To Assets are very stable compared to the past year. As of the 26th of November 2024, Fixed Asset Turnover is likely to grow to 24.98, though Non Currrent Assets Other are likely to grow to (1.7 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| RPh Young | Seres Therapeutics | 57 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Nicole Esq | HCW Biologics | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| David Ege | Seres Therapeutics | 49 | |
| Lisa MD | Seres Therapeutics | 65 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| MD FAAP | Lumos Pharma | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 |
Sunshine Biopharma Leadership Team
Elected by the shareholders, the Sunshine Biopharma's board of directors comprises two types of representatives: Sunshine Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sunshine. The board's role is to monitor Sunshine Biopharma's management team and ensure that shareholders' interests are well served. Sunshine Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sunshine Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Abderrazzak Merzouki, COO and Director | ||
| Camille Sebaaly, CFO, Principal Accounting Officer, Secretary and Director | ||
| Steve Slilaty, Chairman, CEO and Pres | ||
| Robert Ferreira, President Inc | ||
| Malek Chamoun, Chief Officer | ||
| Marc Beaudoin, Chief Officer |
Sunshine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sunshine Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | (6.92 M) | ||||
| Shares Outstanding | 2 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 1.84 % | ||||
| Number Of Shares Shorted | 374.13 K | ||||
| Price To Earning | 1.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.